Form 4: AIM ImmunoTech CEO Thomas Equels Acquires 41,000 Shares of Common Stock
SEC Form 4 Filing
AIM ImmunoTech's CEO, Thomas K Equels, purchased 41,000 shares of common stock at $0.063 per share on April 4, 2025.
Summary
- On April 4, 2025, Thomas K Equels, the CEO and President of AIM ImmunoTech Inc., acquired 41,000 shares of common stock.
- The purchase price was $0.063 per share.
- Following this transaction, Equels directly owns 1,899,029 shares of AIM ImmunoTech Inc.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. Insider buying is generally viewed favorably, but the size of the purchase relative to existing holdings is modest.
Positives
- The CEO's purchase of shares may signal confidence in the company's future prospects.
Industry Context
Insider buying is often seen as a positive sign, suggesting that a company's leadership believes the stock is undervalued.
Stakeholder Impact
- The transaction could have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 04/04/2025 | Date of transaction: Thomas K Equels acquired 41,000 shares of common stock. |
| 04/07/2025 | Date of signature on the Form 4 filing. |
Keywords
AIM ImmunoTech, Thomas K Equels, stock acquisition, Form 4, insider trading, common stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.